A herbal drug, name “BGR-34”, was launched by the Council of Scientific and Industrial Research (CSIR) lab for the diabetes.
The drug has been jointly developed by two CSIR laboratories, National Botanical Research Institute (NBRI) and Central Institute for Medicinal and Aromatic Plant (CIMAP). It was launched on the 62nd annual day of the NBRI for commercial manufacturing and marketing by M/s Aimil Pharamaceuticals Pvt Ltd, New Delhi.
A combination of natural extracts from plants, the drug is based on Ayurveda and has no side effects. The drug is for management of type-II diabetes mellitus.
“The drug has extracts from four plants mentioned in Ayurveda and that makes it safe,” said Dr AKS Rawat, senior principal scientist, NBRI. It has been tested on animals and scientific study has found it safe and effective, with clinical trials showing 67% success.
The drug will help maintain normal blood glucose levels, reduce chances of complications due to persistent high blood glucose levels and impart a good quality life to patients with high blood sugar levels.
The drug boosts immune system, works as antioxidant and checks free radicals. Though there are other anti-diabetes herbal drugs in the market, ‘BGR-34’ has been validated scientifically.
“We will manufacture it now and it will be available in market shortly, may be in the next 15 days,” said V S Kapoor, marketing head of Aimil Pharmaceuticals for UP and Delhi. It will be available in the form of tablets and may cost Rs 500 for 100 tablets.
The formulation was launched earlier by the Vice-President Hamid Ansari in February last year at Vigyan Bhawan, New Delhi, but on Sunday, the product was launched commercially in Lucknow.